Clinical trials: Crohn's Diseases
Crohn Disease
Standardized Microbiota Transplant Therapy in Crohn's Disease
Crohn's disease (CD) develops because of a disruption of homeostasis between the gut microbiota and the host immune system resulting in excessive inflammation in the intestinal tract.
- Trial name
- NCT06631586
- Testing
- MTP-101C, MTP-101S
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Minnesota
Crohn's Disease
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease.
- Trial name
- NCT06430801
- Testing
- IV Tulisokibart, SC Tulisokibart
- Where
- 499 sites in United States, Australia and 45 more
- Volunteers
- 1,200 people
- Sponsor
- Merck Sharp & Dohme LLC
Inflammatory Bowel Diseases, Ulcerative Colitis
Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis
The primary aims of this phase I/II, randomized, placebo controlled study are the assessment of safety and tolerability of universal donor FMT compared to placebo in pediatric and young adult subjects (ages 5 years through 30…
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT02330653
- Testing
- Fecal Microbiota Transplant (FMT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stacy A. Kahn
Crohn's Disease, Inflammatory Bowel Disease
An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease
This study will assess the safety and tolerability of AIN457 in patients with moderate to severe Crohn's disease who already participated and completed the core trial CAIN457A2202.
- Trial name
- NCT01009281
- Testing
- AIN457
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective Humira (adalimumab) is in treating moderately to severely active CD in China.
- Trial name
- NCT05394805
- Where
- 10 sites in China
- Volunteers
- 156 people
- Sponsor
- AbbVie
Polyp of Colon, Crohn Disease
Lesion Size Measurement During Gastrointestinal Endoscopies
The goal of this prospective observational study is to assess the accuracy and reliability of laser readings obtained through AccuMeasure, in comparison to other measurements performed by gastroenterologists.
- Trial name
- AccuMeasure (NCT07770425)
- Where
- Canada
- Volunteers
- 3,000 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Crohn's Disease
Extension Study of Semapimod 60 mg IV x 3 Days
Study CNI-1493-CD06 is an open, single-arm extension studies to CD03 and CD05. CDAI is the only efficacy measure assessed in this study.
- Trial name
- CD06 (NCT00741910)
- Testing
- Semapimod
- Where
- 8 sites in United States, Germany and 2 more
- Volunteers
- 15 people
- Sponsor
- Ferring Pharmaceuticals
Crohn's Disease
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of vedolizumab (MLN0002) in induction and maintenance therapy in…
- Trial name
- NCT02038920
- Testing
- Vedolizumab
- Where
- 56 sites in Japan
- Volunteers
- 157 people
- Sponsor
- Takeda
Crohn's Disease
A Study of Ustekinumab Treatment in Children With Crohn's Disease
The purpose of this study is to evaluate the effectiveness of ustekinumab in achieving clinical remission in pediatric participants (greater than or equal to [>=] 2 to less than [<] 18 years and weight >= 40 kilograms [kg] at…
- Trial name
- REALITI (NCT05242458)
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 545 people
- Sponsor
- Janssen Research & Development, LLC
Inflammatory Bowel Diseases (IBD), Crohn Disease (CD)
NORDTREAT Prospective Study on Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), primarily ulcerative colitis (UC) and Crohn's disease (CD), is a chronic disease entity affecting individuals of all ages, and which may severely impact the lives of the patients and their…
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- NCT05414578
- Where
- 17 sites in Denmark, Iceland and 2 more
- Volunteers
- 366 people
- Sponsor
- University of Southern Denmark
Crohn's Disease
Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease
180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated for improvement of disease activity (efficacy) when taking GLPG0634 or matching placebo once daily for 20 weeks in addition…
- Trial name
- NCT02048618
- Testing
- GLPG0634
- Where
- 63 sites in Belgium, Czechia and 7 more
- Volunteers
- 175 people
- Sponsor
- Lakefront Biotherapeutics NV
Crohn's Disease
Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
This study will assess the safety and efficacy of AIN457 in patients with moderate to severe active Crohn's disease.
- Trial name
- NCT00584740
- Testing
- AIN457
- Where
- 2 sites in Germany
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Crohn Disease
Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)
This is an observational study to determine the prevalence of moderate to severe Crohn's disease (CD) among patients with active CD and to evaluate existing therapeutic trends in a standard clinical practice.
- Trial name
- NCT01218360
- Testing
- Physician standard-of-care
- Volunteers
- 71 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn Disease, Crohn's Ileocolitis
PAtophysiological, Nodal-based Approach for Crohn's Disease Excision
Single centre prospective pilot study on surgery for Crohn's disease (CD). CD universally recurs after surgery and no technique so far has been proven to reduce recurrence.
- Trial name
- PANACEAPILOT (NCT04623476)
- Testing
- Pathophysiological Excision for Crohn's disease
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- University of Rome Tor Vergata
Crohn Disease, Calprotectin
STUDY OF THE ADDED VALUE OF A TRANSMURAL EVALUATION IN PATIENTS WITH CROHN'S DISEASE UNDER BIOTHERAPY WITH CLOSE FECAL CALPROTECTIN FOLLOW-UP
Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that can dramatically affect the quality of life of patients.
- Conditions
- Crohn Disease, Calprotectin, MRI
- Trial name
- Deeper (NCT04973423)
- Testing
- MRI
- Where
- 17 sites in France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Clermont-Ferrand
Crohn's Disease
Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
The purpose of this study is to evaluate the safety of adalimumab for treatment of patients with moderate to severe Crohn's Disease (CD) and to measure the effects of treatment on patient general well-being, health-related…
- Trial name
- NCT00409617
- Testing
- adalimumab
- Where
- 189 sites in Austria, Belgium and 15 more
- Volunteers
- 945 people
- Sponsor
- Abbott
Anemia, Bowel Diseases, Inflammatory
Anemia in Inflammatory Bowel Disease
Anemia is a clinical manifestation, which is commonly observed in patients with inflammatory bowel disease, and it accounts for significant loss in the quality of life of these patients.
- Trial name
- IBD (NCT02760940)
- Testing
- oral liposomal iron
- Volunteers
- 200 people
- Sponsor
- Federal University of Juiz de Fora
Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), Adherence, Patient
Treatment Adherence Among Patients With Inflammatory Bowel Disease Receiving Anti-TNF Therapy
Inflammatory bowel disease (IBD) is a chronic condition characterized by periods of remission and relapse, requiring long-term treatment adherence to maintain disease control and prevent complications.
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), Adherence, Patient, Structured Education
- Trial name
- NCT07652840
- Testing
- Health Belief Model-Based Structured Patient Education, Standard Patient Education
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 140 people
- Sponsor
- Izmir Katip Celebi University
Crohn's Disease
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
A substantial fraction of IBD patients with an initial response to infliximab or adalimumab later experience re-emerging active disease despite ongoing anti-Tumour Necrosis Factor (TNF) agents maintenance therapy.
- Trial name
- VEDIAN (NCT06180382)
- Testing
- Adalimumab, Vedolizumab
- Where
- 12 sites in France
- Volunteers
- 220 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Inflammatory Bowel Disease, Crohn Disease
Deep Endoscopic Remission Assessed by a Surrogate Biomarker in Patients With Inflammatory Bowel Disease
We hypothesize that the number of needed endoscopic procedure performed at IBD patients (adult and children), can be reduced by using an individualized algorithm of symptoms, blood and faecal biomarkers.
- Conditions
- Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis
- Trial name
- NCT01861288
- Where
- Denmark
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.